<SEC-DOCUMENT>0001415889-25-024255.txt : 20250911
<SEC-HEADER>0001415889-25-024255.hdr.sgml : 20250911
<ACCEPTANCE-DATETIME>20250911110531
ACCESSION NUMBER:		0001415889-25-024255
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250910
FILED AS OF DATE:		20250911
DATE AS OF CHANGE:		20250911

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pontifax Management 4 G.P. (2015) Ltd.
		CENTRAL INDEX KEY:			0001726334
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42831
		FILM NUMBER:		251307571

	BUSINESS ADDRESS:	
		STREET 1:		14 SHENKAR STREET, BEIT OFEK
		CITY:			HERZLIYA PITUACH
		STATE:			L3
		ZIP:			46140
		BUSINESS PHONE:		972-9-9725617

	MAIL ADDRESS:	
		STREET 1:		14 SHENKAR STREET, BEIT OFEK
		CITY:			HERZLIYA PITUACH
		STATE:			L3
		ZIP:			46140

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LB PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001691082
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		575 MADISON AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		917-450-6581

	MAIL ADDRESS:	
		STREET 1:		575 MADISON AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LB PHARMACEUTICALS INC.
		DATE OF NAME CHANGE:	20161129
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3-09112025_030927.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-09-10</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001691082</issuerCik>
        <issuerName>LB PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>LBRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001726334</rptOwnerCik>
            <rptOwnerName>Pontifax Management 4 G.P. (2015) Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O LB PHARMACEUTICALS INC</rptOwnerStreet1>
            <rptOwnerStreet2>ONE PENNSYLVANIA PLAZA, SUITE 1025</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10119</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>true</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>411681</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each share of Series C Preferred Stock is convertible at anytime at the option of the holder, without payment of additional consideration, into Common Stock and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering, the Series C Preferred Stock will convert automatically at a conversion ratio that is dependent upon the initial price per share to the public in the Issuer's initial public offering.</footnote>
        <footnote id="F2">Consists of (i) 261,938 shares of common stock issuable upon conversion of shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock issuable upon conversion of shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Asaf Shinar, CFO</signatureName>
        <signatureDate>2025-09-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
